Prescription Drug Abuse: Magnitude and Control

  • R. F. Maronde
  • W. F. Mcghan
  • R. W. O’Neill
  • R. D. Pocrass
  • H. A. Zinszer

Abstract

Overuse of prescription drugs is a controversial topic.1 One of the earliest attempts to control irrational prescribing was instituted by health care insurers in Bavaria immediately after World War II. Prescription drug claims were reviewed and restrictions were instituted.2

Keywords

Insurance Coverage Diazepam Chlordiazepoxide Acetaminophen Pentobarbital 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gagnon, J. P., in Perspectives on Medicines in Society (ed. A. I. Wertheimer and P. J. Bush). Drug Intelligence Publications, Hamilton, Ill. (1977)Google Scholar
  2. 2.
    Laurbach, E., Secretary of Health and Education, Bavaria, West Germany, personal communication (1971)Google Scholar
  3. 3.
    Harris, R., The New Yorker, 14 March 1964Google Scholar
  4. 4.
    Harris, R., The New Yorker, 21 March 1964Google Scholar
  5. 5.
    Harris, R., The New Yorker, 28 March 1964Google Scholar
  6. 6.
    Office of the Secretary, United States Department of Health, Education and Welfare, Task Force on Prescription Drugs, Final Report, US Government Printing Office, Washington, D.C. (1969)Google Scholar
  7. 7.
    Office of the Secretary, United States Department of Health, Education and Welfare, The Drug Users, US Government Printing Office, Washington, D.C. (1968)Google Scholar
  8. 8.
    Office of the Secretary, United States Department of Health, Education and Welfare, The Drug Makers and Drug Distribution, US Government Printing Office, Washington, D.C. (1969)Google Scholar
  9. 9.
    Office of the Secretary, United States Department of Health, Education and Welfare, Approaches to Drug Insurance Design, US Government Printing Office, Washington, D.C. (1969)Google Scholar
  10. 10.
    Office of the Secretary, United States Department of Health, Education and Welfare, The Drug Prescribers, US Government Printing Office, Washington, D.C. (1969)Google Scholar
  11. 11.
    Muller, C., J. chron. Dis., 18, 688 (1965)Google Scholar
  12. 12.
    Furstenberg, F. F., Talback, M., Goldberg, H., et al., Am. J. publ. Hlth, 43, 1299 (1953)Google Scholar
  13. 13.
    Teplesky, B., Am. Proj. Pharm., 21, 816 (1955)Google Scholar
  14. 14.
    Coleman, J. S., Kotz, E., and Menzel, H., Sociometry, 20, 253 (1957)Google Scholar
  15. 15.
    Winuk, C., Sociometry, 24, 384 (1961)Google Scholar
  16. 16.
    Martin, J. P., Social Aspects of Prescribing, Heinemann, London (1957)Google Scholar
  17. 17.
    Wilson, C. W. M., Banks, J., Mapes, R. E. A., and Korte, S. M. P., Br. med. J. ii, 604 (1962)Google Scholar
  18. 18.
    Lee, J. A. H., Proc. R. Soc. Med., 57, 1041 (1964)Google Scholar
  19. 19.
    Lee, J. A. H., Draper, D. A., and Weatherall, M., Milbank Mem. Fd Quart., 43 (21), 285 (1965)Google Scholar
  20. 20.
    Cluff, L. E., Hosp. Pract., 2, 100 (1967)Google Scholar
  21. 21.
    Seibert, S., Brunjes, S., Soutter, J., and Maronde, R. F. Drug Intell., 1, 342 (1967)Google Scholar
  22. 22.
    Maronde, R. F., Burks, D., Lee, P. V., et al., J. Hosp. Pharm., 26, 566 (1969)Google Scholar
  23. 23.
    Stolley, P. D., and Lasagna, L., J. chron. Dis., 22, 395 (1969)Google Scholar
  24. 24.
    Maronde, R. F., Drug Utilization Review with On-line Computer Capability; Selected Methodology and Finding from a Demonstration, United States Department of Health, Education and Welfare, Social Security Administration, Office of Research Statistics, Staff Paper no. 13, DHEW Publication no. SSA73–11855 (1973)Google Scholar
  25. 25.
    Brodie, D. C., Drug Utilization and Drug Utilization Review and Control, Department of Health, Education and Welfare, National Center for Health Services Research and Development, NCHS-RD-70–8 (1978)Google Scholar
  26. 26.
    Maronde, R. F., Lee, P. V., McCarron, M., et al., Med. Care, 9, 383 (1971)Google Scholar
  27. 27.
    Maronde, R. F., Seibert, S., Katzoff, J., et al., Calif. Med., 117, 22 (1972)Google Scholar
  28. 28.
    Maronde, R. F., and Silverman, M., Ann. intern. Med., 79, 452 (1973)Google Scholar
  29. 29.
    Health Technology Inc., Report on Abuse of Drugs Dispensed under the Medi-Cal Program, 1978, Chief of Surveillance and Utilization Review Section, California State Department of Health Services (1978)Google Scholar
  30. 30.
    Maronde, R. F., and Rucker, T. D., paper presented at the meeting of the World Association of Medical Informatics, 19&;#x2013;22 March 1977Google Scholar
  31. 31.
    Silverman, M., and Lee, P. Pills, Profits and Politics, University of California Press, Stanford (1974)Google Scholar
  32. 32.
    Ray, W. A., Federspeil, W., and Schaffer, W., in Proceedings of the 2nd Annual Meeting, World Association of Medical Informatics (ed. F. Began), Poitiers (1979)Google Scholar
  33. 33.
    Smith, D. E., and Weson, D. R., Uppers and Downers, Prentice-Hall, Englewood Cliffs, N.J.Google Scholar
  34. 34.
    Reasons, G., and Goodman, M., Los Angeles Times, 23 March 1978Google Scholar
  35. 35.
    Palmieri, R. A., Chief Pharmaceutical Consultant, Surveillance and Utilization Review Section, Department of Health Services, State of California, personal communications (1978)Google Scholar
  36. 36.
    Reasons, G., and Goodman, M., Los Angeles Times, 27 September 1978Google Scholar
  37. 37.
    Attack on drug abuse: A report on control efforts in California, US Department of Health, Education and Welfare, Health Care Financing Administration, Office of Program Integrity, Region IX, San Francisco (1979)Google Scholar
  38. 38.
    Maronde, R. F., Hearings before the Select Committee on Narcotics Abuse and Control. House of Representatives, 95th Congress, 2nd Session, SCNAC 95–2-22, US Government Printing Office, Washington, D.C. (1979), pp. 199, 244Google Scholar
  39. 39.
    A report of the Select Committee on Narcotics Abuse and Control, 95th Congress, SNAC 95–2-16, US Government Printing Office, Washington, D.C. (1979), p. 13Google Scholar
  40. 40.
    Stolar, M. H., Am. J. Hosp. Pharm., 34, 139 (1977)Google Scholar
  41. 41.
    Brandon, B. M., Knapp, D. A., Klein, L. S., et al., Am. J. Hosp. Pharm., 34, 1946 (1977)Google Scholar
  42. 42.
    Brodie, D. D., and Smith, W. E., Hospitals, 50, 143, 146, 148 (1976)Google Scholar
  43. 43.
    Flock, E. E., and Sanazaro, P. J., Health Services Research and R and D in Perspective, Health Administration Press, University of Michigan, Lansing, Mich. (1972), chap. 1Google Scholar
  44. 44.
    Conley, B. E., in Computer Aid to Drug Therapy and to Drug Monitoring (ed. H. Ducrot, H. M. Goldberg, M. R. Hoigne, and P. Middleton), North Holland Press, Amsterdam (1978)Google Scholar
  45. 45.
    Health United States, US Health and Human Services, PHS, Office of Health Research, Statistics and Technology (1978), p. 213Google Scholar
  46. 46.
    Pharmaceutical Benefits Under State Medical Assistance Programs, National Pharmaceutical Council, Washington, D.C. (1979)Google Scholar
  47. 47.
    Information provided by the staff of Health Care Finance Administration (HCFA), Bethesda, MdGoogle Scholar
  48. 48.
    Maronde, R. F., McGhan, W., O&;#x2019;Neill, R., Pocrass, R., and Zinszer, H., in Proceedings of the Fourteenth Annual Hawaii Conference on Systems Sciences, University of Hawaii, Honolulu (1981)Google Scholar
  49. 49.
    Social Cost of Drug Abuse, Special Action Office on Drug Abuse Prevention, Washington, D.C. (1974)Google Scholar
  50. 50.
    Hearings before the Select Committee on Narcotics Abuse and Control, House of Representatives, 95th Congress, Second Session, August 8, 10, September 19 and October 6, 1978, SCNAC 95–2-22, US Government Printing Office, Washington, D.C. (1979)Google Scholar
  51. 51.
    Fiscal Impact of S. 714; A Discussion Paper, Pracon Inc., Va, presented before Legislative Committee, State of California, 27 May 1981Google Scholar
  52. 52.
    White, W., Chief of Beneficiary Utilization Review Unit, Department of Health Services, State of California, personal communicationGoogle Scholar
  53. 53.
    Maronde, R. F., in Perspectives on Medicines in Society (ed. A. I. Wertheimer and P. J. Bush), Drug Intelligence Publications, Hamilton, Ill. (1977)Google Scholar
  54. 54.
    Maronde, R. F., in pressGoogle Scholar
  55. 55.
    Dallos, R. F., Los Angeles TImes, 7 July 1981Google Scholar

Copyright information

© The Royal Society of Medicine 1983

Authors and Affiliations

  • R. F. Maronde
  • W. F. Mcghan
  • R. W. O’Neill
  • R. D. Pocrass
  • H. A. Zinszer

There are no affiliations available

Personalised recommendations